AMLX News and Press, Amylyx Pharmaceuticals Inc.

2024-06-25 15:35:59 ET Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 ...

2024-06-22 09:11:45 ET More on Amylyx, Eiger, etc. Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript Amylyx Pharmaceuticals Q1 2024 Earnings Preview Amylyx down 6% despite encouraging phase 2 data on rare disorder drug Seeking Alpha’...

2024-06-15 15:37:28 ET The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%.... Read the full article on Seeking Alpha For further details see: ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...

2024-05-10 16:30:03 ET H.C. Wainwright analyst issues BUY recommendation for AMLX on May 10, 2024 02:01PM ET. The previous analyst recommendation was Buy. AMLX was trading at $1.775 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-05-09 10:40:09 ET Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Results Conference Call May 09, 2024 08:00 AM ET Company Participants Lindsey Allen - Head, IR & Communications Justin Klee - Co-CEO Camille Bedrosian - CMO Jim Frates - CFO Josh Cohen...

2024-05-09 07:16:29 ET More on Amylyx Pharmaceuticals An ALS Drug Fails Again Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Amylyx Pharmaceuticals Q1 2024 Earnin...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Company plans to engage with FDA based on interim data from the Phase 2 HELIOS clinical trial demonstrating improvements in pancreatic function, glycemic control, and vision in participants with Wolfram syndrome treated with AMX0035; topline data from all 12 participants at Week 24 anticipated in...

2024-05-08 12:34:51 ET Major earnings expected before the bell on Thursday include: Medical Properties Trust ( MPW ) Plug Power ( PLUG ) Roblox ( RBLX ) Viatris ( VTRS ) Warner Bros. Discovery ( WBD ) Read the full article on Seeking Alpha ...